- within Food, Drugs, Healthcare and Life Sciences topic(s)
- with Inhouse Counsel
- in United States
- with readers working within the Business & Consumer Services, Healthcare and Media & Information industries
On July 9, 2026, Teva Pharmaceutical Industries and Samsung Bioepis announced they have entered into a license and commercialization agreement for OPUVIZ® (aflibercept), Samsung Bioepis’s biosimilar referencing Regeneron’s EYLEA®, in Canada. Under the agreement, Samsung Bioepis will remain responsible for product registration and manufacturing, while Teva Canada will lead commercialization efforts.
OPUVIZ received Health Canada approval in October 2025 for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), visual impairment due to macular edema following central or branch retinal vein occlusion (CRVO/BRVO), and myopic choroidal neovascularization (mCNV).
Outside Canada, OPUVIZ is already marketed in Europe and the Republic of Korea. Teva Canada has indicated that additional details regarding the timing of the Canadian commercial launch will be announced at a later date.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]